Our results showed that preservation of the EGFR-mediated signal transduction pathway is a necessary condition for EGFR molecular-targeted therapy with gefitinib in anaplastic thyroid cancer cell lines. This evidence concerns the gene EGFR and thyroid gland undifferentiated (anaplastic) carcinoma.